As of the close of trading at noon on January 21, 2025, the Hong Kong stock pharmaceutical ETF (159718) was long and short, with the latest price of 0.57 yuan, and the half-day turnover has reached 10.356 million yuan, with a turnover rate of 4.84%. The CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 0.68%, the constituent stocks Zai Lab (09688) rose 3.89%, Federated Pharmaceuticals (03933) rose 3.78%, Ali Health (00241) rose 3.55%, InnoCare (09969) rose 3.19%, and JD Health (06618) rose 2.70%.

The latest price of medical innovation ETF (516820) is 0.32 yuan, and the half-day turnover has reached 23.44 million yuan. The CSI Pharmaceutical and Medical Device Innovation Index (931484), which tracks the index, fell 0.34%. In terms of constituent stocks, Yirui Technology (688301) led by 3.31%, Huitai Medical (688617) rose 2.46%, and Aibo Medical (688050) rose 1.77%; Allist (688578) led the decline by 6.67%, Jiudian Pharmaceutical (300705) fell 2.56%, and Xinmai Medical (688016) fell 1.76%.

In the long run, as of January 20, 2025, Hong Kong stock pharmaceutical ETFs have risen by 4.60% in the past week. Medical innovation ETF has risen by 3.16% in the past 1 week, ranking 1/2 of comparable funds.

In terms of scale, the scale of medical innovation ETF has increased by 17.4819 million yuan in the past week, achieving significant growth, and the new scale ranks 1/2 of comparable funds. In terms of shares, the shares increased by 34 million shares in the past one week, achieving significant growth, and the new shares ranked 1/2 of comparable funds.

From the perspective of net inflow of funds, medical innovation ETF has received continuous net inflow of funds in the past four days, with the highest net inflow of 6.7489 million yuan in a single day, with a total of 10.9096 million yuan and an average daily net inflow of 2.7274 million yuan.

The data shows that leveraged funds continue to be deployed. The latest financing purchase amount of medical innovation ETF reached 2.4552 million yuan, and the latest financing balance reached 81.4867 million yuan.

From the perspective of valuation, the latest price-to-earnings ratio (PE-TTM) of the CSI Hong Kong Stock Connect Medical and Health Composite Index tracked by the Hong Kong Pharmaceutical ETF is only 29.03 times, which is at the quantile of 17.41% in the past five years, that is, the valuation is lower than the time of more than 82.59% in the past five years, which is at a historical low.

It is worth noting that the valuation of the CSI Pharmaceutical and Medical Device Innovation Index tracked by the Medical Innovation ETF is at a historical low, with the latest price-to-book ratio of 4.48 times, which is lower than the index of more than 84.93% in the past five years, and the valuation is cost-effective.

Recently, the National Health Insurance Administration held a press conference on the theme of "Protecting People's Health and Empowering Economic Development" of the medical insurance department, and the relevant person in charge of the National Health Insurance Bureau said that the first version of the medical insurance category C catalog will be released in 2025. As an effective supplement to the list of basic medical insurance drugs, the Category C catalogue focuses on drugs that cannot be included in the catalogue temporarily due to the functional positioning of "guaranteeing the basics", but have a high degree of innovation, significant clinical application value, and significant benefits for patients. The National Health Insurance Administration will take a variety of incentive measures to actively guide and support Huimin-type commercial health insurance products to include Class C listed drugs in the scope of product liability protection. At the same time, it will also open up the channel between the Category C catalogue and the basic medical insurance catalogue to do a good job of cohesion.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of December 31, 2024, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) were WuXi Biologics (02269), BeiGene (06160), Innovent Biologics (01801), Akeso Biologics (09926), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), JD Health (06618), Sinopharm Group (01099), Zai Lab (09688), and WuXi AppTec(02359), the top ten weighted stocks accounted for 57.44%.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of December 31, 2024, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are Mindray Medical (300760), WuXi AppTec (603259), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Medical (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Zhifei Biotechnology (300122), and Huadong Medicine ( 000963) and new industries (300832), the top ten weighted stocks accounted for 66.25% of the total.